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Associations between body mass index and serum levels of 
C-reactive protein
Tung-Wei Kao, I-Shu Lu, Kuo-Chen Liao, Hsiu-Yun Lai, Ching-Hui Loh, Hsu-Ko Kuo
C-reactive protein (CRP) (an acute phase protein) has been 
thought to be synthesised in the liver, with a plasma half-life 
of 18 hours.1 However, the extrahepatic expression of CRP 
has been detected in macrophages and smooth-muscle cells 
from atherosclerotic plaques.2 It plays an important role in the 
inflammatory process and is recognised as a useful biochemical 
marker of inflammation. Increasing epidemiological 
evidence supports the notion that low-grade inflammation, 
as reflected by elevated levels of CRP, is associated with 
glucose intolerance3 and various vascular diseases4-7 including 
atherosclerosis, stroke, ischaemic heart disease, and peripheral 
vascular disease. Evidence-based systemic reviews have 
suggested that elevated CRP is related to an increased risk of 
stroke and cognitive impairment.8
There is evidence for the presence of CRP in human adipose 
tissue9,10 and growing evidence that adipose tissue can 
induce chronic low-grade inflammation by producing pro-
inflammatory cytokines such as interleukin-6.11 Overweight 
or obese individuals have an increased risk of developing 
cardiovascular diseases12 and insulin resistance.13 A certain 
degree of inflammatory process in subjects with obesity 
could be suspected, but data examining the direct association 
between body mass index (BMI) and CRP is sparse. This study 
aimed to evaluate whether higher BMI and central obesity are 
associated with low-grade systemic inflammation as measured 
by serum CRP levels, using data from the National Health and 
Nutrition Examination Survey (NHANES), 1999 - 2002.
Materials and methods
Participants
The National Health and Nutrition Examination Survey 
(NHANES) is a population-based survey to collect information 
on the health and nutrition of the USA’s domestic population. 
NHANES used a stratified, multistage and cluster sampling 
design to obtain a representative sample of the non-
institutionalised civilian USA population by conducting 
detailed home interviews and health examinations in a mobile 
examination centre. Since 1999, NHANES became a continuous 
annual survey rather than its past form of a periodic survey. 
Our study population comprised adults aged ≥20 years who 
participated in the NHANES 1999 - 2002. Detailed survey 
operations manuals, consent documents and brochures of 
NHANES 1999 - 2002 are available on its website.14,15
A total of 10 291 participants aged ≥20 years were included. 
Body measurements in some participants could not be obtained 
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Background. Obesity leads to increased risk of cardiovascular 
disease and glucose intolerance, which are phenomena of 
chronic inflammation. This study was performed to determine 
whether a higher body mass index (BMI) and central obesity 
are associated with low-grade inflammation.
Methods. An analysis of 8 453 adults aged ≥20 years was 
performed. Every subject completed a household interview 
and a questionnaire regarding personal health, and their BMI 
and serum C-reactive protein (CRP) level were measured. The 
BMI data were divided into quintiles, using multiple linear 
regression to estimate the relationship between CRP level and 
BMI quintiles. An extended-model approach was used for 
covariate adjustment. The association between central obesity 
and CRP level was examined by this method as well.
Results. After controlling for demographics, chronic diseases, 
health behaviours and levels of folate and vitamin B12, 
the β coefficient (which represents the change of natural-
log-transformed levels of CRP for each kg/m2 increase in 
BMI) was 0.078 (p<0.001). The CRP levels also increased 
across increasing quintiles of BMI (p for trend <0.001). 
The β coefficient, representing the change of natural-log-
transformed levels of CRP comparing subjects with central 
obesity to those without, was 0.876 (p<0.001).
Conclusion. Higher BMIs as well as central obesity are 
independently associated with higher levels of CRP.
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because of safety concerns, refusals or physical limitations 
(such as the participant being confined to a wheelchair); 
of these, 1 402 were excluded from the analysis because of 
missing BMI values (N=1 227) and waist measurements 
(N=175), and 436 were excluded because of unavailable data on 
CRP. Therefore, the final sample comprised 8 453 adults who 
completed a household interview and laboratory and clinical 
examinations.
Body measurements
Generally, height and weight were not obtained for subjects 
using a wheelchair in the mobile examination centre. Height 
was measured with a stadiometer to the nearest 0.1 cm. Weight 
was measured with a Toledo digital scale and recorded to 
the nearest 0.01 kg. BMI was calculated as mass in kilograms 
divided by the square of height in metres. Waist circumference 
was measured on the horizontal plane at the level of the 
uppermost border of the bilateral iliac crests.
C-reactive protein measurements
Blood specimens were collected at the mobile examination 
centres and analysed at the Department of Laboratory 
Medicine, University of Washington. CRP was analysed by 
a highly sensitive assay technique. Standard phlebotomy 
techniques were used to obtain specimens, which were held at 
–20°C until used for laboratory analysis. CRP was quantified 
by utilising latex-enhanced nephelometry with a Behring 
nephelometer (Deerfield, USA). Results were reported to the 
nearest hundredth (0.01) unit. The lowest reportable CRP result 
is approximately 0.02 mg/dl; this varies slightly with different 
calibrator lots. The assay does not have a maximum reportable 
limit since the instrument automatically prepares a higher 
dilution and retests specimens with results above the linearity 
of the assay to obtain reactions within the linear range for the 
assay. Detailed specimen collection and processing instructions 
are discussed in the NHANES Laboratory Procedures Manual.
Covariates
Age, sex, race/ethnicity, and smoking status were self-
reported. Diabetes was defined by the self-reporting of 
a physician’s diagnosis, or random plasma glucose ≥200 
mg/dl, or the use of diabetic medications (including 
insulin injection or oral hypoglycaemic agents). Three, and 
sometimes four, blood pressure (BP) tests were done, using a 
mercury sphygmomanometer, by a NHANES physician. BP 
was measured via the right arm unless specific conditions 
prohibited its use. Average systolic and diastolic BPs were 
obtained. The presence of hypertension was defined by a 
self-reported doctor’s diagnosis, the use of antihypertensive 
medications, or average blood pressure ≥140/90 mmHg. 
Medical histories of myocardial infarction (>6 weeks), 
congestive heart failure, angina, chronic bronchitis, emphysema 
and arthritis were ascertained by self-report. Alcohol intake 
was determined by the question: ‘In any one year, have you 
had ≥12 drinks of any type of alcohol beverage?’ Serum 
folate levels were measured using a commercially available 
radioprotein binding assay kit, the Quantaphase II Folate/
vitamin B12 radio-assay kit (Bio Rad Laboratories, Hercules, 
CA, USA). Detailed specimen collection and processing 
instructions are in the NHANES Laboratory Procedures 
Manual and on their website.15
Statistical analysis
The distributions of CRP serum levels in the population were 
right-skewed. Therefore, the values of CRP were natural-
log-transformed, providing a best-fitting model for analysis 
in which the serum CRP levels were treated as a continuous 
variable. We used multiple linear regression to determine the 
change of natural-log-transformed levels of CRP for each kg/
m2 increase in BMI, and quintile-based analysis by dividing 
BMI into quintiles with the subjects in the lowest BMI quintile 
as the reference group. The cut-off levels for BMI quintiles 
were: Q1 – BMI <23.32 kg/m2; Q2 – BMI ≥23.32 - 26.07 kg/m2; 
Q3 – BMI ≥26.08 - 28.73 kg/m2; Q4 – BMI ≥28.74 - 32.53 kg/m2; 
Q5 – BMI >32.53 kg/m2. The β coefficients were interpreted 
as the differences in mean natural-log-transformed CRP levels 
comparing subjects in the upper four BMI quintiles with those 
in the lowest quintile. Central obesity was defined as waist 
circumference >102 cm in males, and >88 cm in females. The β 
coefficients were interpreted as the differences in mean natural-
log-transformed CRP levels comparing subjects with central 
obesity with those without. An extended-model approach was 
used for covariate adjustment: model 1= age, gender, race; 
model 2 = model 1 plus levels of vitamin B12 and folate; model 
3 = model 2 plus chronic diseases (hypertension, diabetes 
mellitus, heart disease, stroke) and health behaviours (smoking 
status and alcohol consumption). All analyses were conducted 
using STATA version 8.0 (Stata Corporation, College Station, 
TX, USA).
Results
The characteristics of the study subjects are summarised in 
Table I. Concerning chronic diseases, 38.9% of the subjects were 
hypertensive and 11.4% had diabetes mellitus; 49.1% were non-
Hispanic Caucasian; and participants with higher BMIs tended 
to have a high level of CRP.
In the linear model, CRP levels positively correlated with 
BMI. After adjusting for age, gender and race (model 1), the β 
coefficient, representing the change of natural-log-transformed 
levels of CRP for each kg/m2 increase in BMI, was 0.080 
(p<0.001) (Table II). The correlation remained unchanged after 
additionally adjusting for other covariates in models 2 and 3 
(Table II). The results of BMI quintile-based multiple linear 
regression analysis are shown in Table III. From model 1 to 
model 3, we observed positive correlations between BMI and 
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CRP levels. Subjects in the higher quintiles of BMI tended to 
have higher CRP levels (Fig. 1). The trends of CRP levels across 
BMI quintiles were all statistically significant.
CRP levels were higher in subjects with central obesity (Fig. 
2). After controlling for age, gender and race, the β coefficient, 
reflecting the change of natural-log-transformed levels of CRP 
comparing subjects with central obesity with those without, 
was 0.876 (p<0.001). Additional adjustment of covariates did 
not change the correlation (Table IV).
Discussion
This study demonstrates a positive correlation between BMI 
and serum CRP, supporting and extending previous studies 
showing that elevated plasma levels of CRP are associated 
with obesity.16, 17 Unlike this study, previous studies had 
weaknesses in terms of weight categorisation, with strikingly 
uneven subject numbers among different weight groups.16,17 
Stratifying the BMIs into quintiles, we tried to quantify the 
correlation between BMI and inflammation, and to investigate 
whether fat distribution, especially abdominal girth, is 
independently associated with CRP levels. Our finding that 
subjects with central obesity seemed to have higher CRP levels 
is compatible with other reports suggesting that a high waist-
to-hip ratio and increased abdominal visceral fat have links 
with insulin resistance, hypertriglyceridaemia, hypertension, 
dyslipidaemia18 and chronic low-grade inflammation.16,18 
Combining our observations with those in previous reports, it 
can be concluded that the high prevalence of chronic diseases 
among overweight and obese subjects – including insulin 
resistance, diabetes and cardiovascular disease – may be 
Table I. Characteristics of study participants
      Quintile of BMI (kg/m2)
   Q1  Q2  Q3  Q4  Q5 
Characteristic  (<23.32)  (23.32 - 26.07) (26.08 - 28.73) (28.74 - 32.53) (>32.53)            Total
Continuous variables*
Age (yrs)  45.5 (19.9) 49.2 (19.5) 50.7 (18.5) 50.7 (17.4) 47.9 (16.6) 
Blood pressure (mmHg)
Systolic  121.0 (21.7) 124.5 (21.1) 126.1 (20.6) 127.5 (19.9) 128.3 (19.3)
Diastolic  69.2 (13.6) 69.2 (14.4) 71.2 (14.1) 72.2 (13.8) 73.8 (13.4) 
Waist (cm)  79.1 (7.3)  89.2 (6.9)  96.3 (7.2)  102.9 (7.5) 116.2 (12.1)
C-reactive protein (mg/dl)† 0.11 (0.04 - 0.29) 0.17 (0.07 - 0.39) 0.22 (0.1 - 0.46) 0.29 (0.14 - 0.57) 0.5 (0.26 - 0.93)
Vitamin B12 (pg/ml)
† 482 (373 - 647) 482 (348 - 636) 459 (348 - 610) 459 (350 - 591) 441 (336 - 581)
Folate (ng/ml)†  13.4 (9.3 - 18.9) 13.6 (9.6 - 18.9) 13.2 (9.4 - 18.4) 12.8 (9.3 - 17.8) 11.7 (8.6 - 16.9)
Categorical variables‡
Male   718 (42.4)  872 (51.6)  917 (54.3)  873 (51.5)  607 (36.0)            3 987 (47.2)
Race
Mexican  311 (18.4)  414 (24.5)  465 (27.5)  464 (27.4)  406 (24.1)            2 060 (24.4)
Hispanic  83 (4.9)  86 (5.1)  111 (6.6)  85 (5.0)  81 (4.8)            446 (5.3)
Non-Hispanic white 940 (55.5)  871 (51.6)  815 (48.2)  792 (46.7)  736 (43.7)            4 154 (49.1)
Non-Hispanic black 285 (16.8)  258 (15.3)  245 (14.5)  318 (18.8)  418 (24.8)            1 524 (18.0)
All others  75 (4.4)  60 (3.6)  54 (3.2)  36 (2.1)  44 (2.6)            269 (3.2)
Diabetes mellitus  72 (4.3)  137 (8.1)  194 (11.5)  232 (13.7)  330 (19.6)            965 (11.4)
Hypertension  439 (25.9)  554 (32.8)  670 (39.6)  755 (44.5)  876 (52.0)            3 294 (38.9)
Current smoker  537 (31.7)  390 (23.1)  368 (21.8)  344 (20.3)  297 (17.6)            1 936 (22.9)
Ever had diagnosis of
Stroke   26 (1.5)  41 (2.4)  56 (3.3)  53 (3.1)  57 (3.4)            233 (2.8)
Heart attack  49 (2.9)  62 (3.7)  73 (4.3)  70 (4.1)  75 (4.5)            329 (3.9)
Congestive heart failure 23 (1.4)  44 (2.6)  54 (3.2)  49 (2.9)  56 (3.3)            226 (2.7)
Coronary heart disease 41 (2.4)  65 (3.9)  78 (4.6)  81 (4.8)  65 (3.9)            330 (3.9)
Alcohol consumption
≥12 drinks per year 1 119 (66.1) 1 129 (66.8) 1 121 (66.3) 1 130 (66.7) 957 (56.8)            5 456 (64.6)
*Values in the continuous variables were expressed as mean (standard deviation) unless otherwise specified.
†Values were expressed as median (interquartile range) owing to right skewness.
‡Values in the categorical variables were expressed as number (%).
Table II. Association between BMI and levels of C-reactive 
protein
Models*   β (SE)†  p-value
Model 1   0.080 (0.002) <0.001
Model 2   0.080 (0.002) <0.001
Model 3   0.078 (0.002) <0.001
*Adjusted covariates: model 1 = age, gender, race; model 2 = model 1 + serum level of 
folate, vitamin B12; model 3 = model 2 + chronic diseases and health behaviours.
†β coefficient was interpreted as change of natural-log-transformed levels of C-
reactive protein for each kg/m2 increase in BMI.
SE = standard error.
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explained by the finding of higher CRP levels, indicating that a 
certain degree of inflammation is present in these populations.
Subjects with obesity tend to have more abdominal visceral 
adipocytes, which are supposed to produce almost 25% of 
systemic interleukin-6 in vivo;19 and CRP could be stimulated 
by cytokines such as interleukin-1-beta, interleukin-6 and 
tumor necrosis factor-α. Consequently, adipose tissue could 
play a role in the regulation of circulating CRP levels via 
interleukin-6 production; this may partially explain our study’s 
findings of why subjects with central obesity have higher 
serum levels of CRP.
Table III. Association between BMI quintiles and levels of C-reactive protein
Models*   BMI quintiles†  β (SE)‡            p-value       p for trend
Model 1   Q2 v. Q1   0.407 (0.039)           <0.001
   Q3 v. Q1    0.666 (0.039)           <0.001  <0.001
   Q4 v. Q1   0.914 (0.039)           <0.001
   Q5 v. Q1   1.395 (0.039)           <0.001
Model 2   Q2 v. Q1   0.406 (0.039)           <0.001
   Q3 v. Q1   0.663 (0.039)           <0.001  <0.001
   Q4 v. Q1   0.913 (0.039)           <0.001
   Q5 v. Q1   1.393 (0.039)           <0.001
Model 3   Q2 v. Q1   0.426 (0.039)           <0.001
   Q3 v. Q1   0.674 (0.039)           <0.001  <0.001
   Q4 v. Q1   0.912 (0.039)           <0.001
   Q5 v. Q1   1.357 (0.040)           <0.001
*Adjusted covariates: model 1 = age, gender, race; model 2 = model 1 + serum level of folate, vitamin B12; model 3 = model 2 + chronic diseases and health behaviours.†Subjects in the lowest BMI quintiles were the reference group.
‡β coefficients can be interpreted as differences in mean natural-log-transformed C-reactive protein levels comparing subjects in the upper four BMI quintiles with those in the lowest 
quintile.
SE = standard error.
Fig. 1. Association between BMI quintiles and levels of C-reactive protein. With an increase in
BMI, the levels of CRP increased. Q1 (<23.32 kg/m2), Q2 (23.32 to 26.07 kg/m2), Q3
(26.08 to 28.73 kg/m2), Q4 ( 28.74 to 32.53 kg/m2) and Q5 ( >32.53 kg/m2). Each value
of CRP was reversed from the natural-log-transformed CRP of each BMI quintile. The
upper and lower bars indicate the 95% confidence interval (CI) reversed from the 95% CI
of natural-log-transformed CRP in each BMI quintile.
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Fig. 1. Association between BMI quintiles and levels of C-reactive protein. 
With an increase in BMI, the levels of CRP increased. Q1 (<23.32 kg/m2), 
Q2 (23.32 to ≤26.07 kg/m2), Q3 (26.08 to ≤28.73 kg/m2), Q4 ( 28.74 to 
≤32.53 kg/m2) and Q5 ( >32.53 kg/m2). Each value of CRP was reversed 
from the natural-log-transformed CRP of each BMI quintile. The upper 
and lower bars indicate the 95% confidence interval (CI) reversed from the 
95% CI of natural-log-transformed CRP in each BMI quintile.
Fig. 2. Association between central obesity and levels of C-reactive protein. Subjects with
central obesity had higher levels of CRP. Each value of CRP was rev rsed from the natural-log-
transformed CRP of each category. The upper and lower bars indicate the 95% confidence
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Fig. 2. Association between central obesity and levels of C-reactive protein. 
Subjects with central obesity had higher levels of CRP. Each value of CRP 
was reversed from the natural-log-transformed CRP of each category. The 
upper and lower bars indicate the 95% confidence interval (CI) reversed 
from the 95% CI of natural-log-transformed CRP in each category.
Table IV. Association between central obesity* and levels 
of C-reactive protein
Models†   β (SE)‡  p-value
Model 1   0.876 (0.026) <0.001
Model 2   0.874 (0.026) <0.001
Model 3   0.825 (0.027) <0.001
*Central obesity was defined as waist circumference in males >102 cm, in females 
 >88 cm.
†Adjusted covariates: model 1 = age, gender, race; model 2 = model 1 + serum level of 
folate, vitamin B12; model 3 = model 2 + chronic diseases and health behaviours.‡β coefficient was interpreted as change of natural-log-transformed levels of C-
reactive protein comparing subjects with central obesity with those without.
SE = standard error.
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Our study has the following implications: firstly, subjects 
with a higher BMI tend to have higher CRP levels, indicating 
that overweight or obese adults are vulnerable to adverse 
outcomes of chronic inflammation such as myocardial 
infarction and stroke. Weight reduction has been demonstrated 
to reduce CRP20 or interleukin-6 levels.21 Aggressive weight 
control could potentially minimise the threat of cardiovascular 
diseases. Further prospective studies to investigate the 
influence of weight reduction, lifestyle modifications and 
weight control agents on inflammatory markers are necessary. 
The second implication is that a strong correlation exists 
between central obesity and CRP levels, after adjusting for 
possible confounding factors. Abdominal girth is viewed as 
one of the criteria for metabolic syndrome, and reduction of 
waist circumference is considered to be crucial in reducing the 
risk of inflammation.
There are some limitations to our study. Because of 
the cross-sectional design, causality between obesity and 
serum CRP level could not be established. Additional data 
regarding interleukin-6 or tumour necrosis factor-α is absent 
from NHANES. Since these factors play major roles in 
the inflammatory process, a concrete association between 
interleukin-6, tumour necrosis factor-α and weight status could 
possibly be obtained from further examination.
Conclusion
Higher BMIs are associated with higher CRP levels in this 
population-based cross-sectional study. Subjects with central 
obesity tend to have higher levels of CRP independent of major 
confounding variables. Aggressive weight reduction could be 
a worthwhile intervention to reduce inflammation-associated 
adverse outcomes in overweight and obese subjects.
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